Sanofi (BMV:SAN1 N) - Cotización, noticias y análisis

Resumen de acción SAN1 N

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally.

Acerca de la empresa

SAN1 N fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	0/6
Past Performance	5/6
Financial Health	6/6
Dividends	5/6

Recompensas

Cotiza un 42.4% por debajo de nuestra estimación de su valor justo

Los beneficios aumentaron un 41.5% el pasado año

Paga dividendo fiable de 3.87%

Análisis de riesgos

Acciones altamente ilíquidas

Competidores de Sanofi

Genomma Lab Internacional. de

BMV:LAB B

Mex$13.6b

Pfizer

NYSE:PFE

US$149.0b

Bristol-Myers Squibb

NYSE:BMY

US$99.3b

GSK

LSE:GSK

UK£66.8b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Sanofi
Historical stock prices
Current Share Price	€1,629.20
52 Week High	€1,978.38
52 Week Low	€1,609.59
Beta	0.43
1 Month Change	0%
3 Month Change	1.22%
1 Year Change	-11.35%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-20.61%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	SAN1 N	MX Pharmaceuticals	Mercado MX
7D	0%	2.0%	1.5%
1Y	-11.4%	-15.4%	2.6%

Rentabilidad vs. Industria: SAN1 N superó al sector MX Pharmaceuticals , que obtuvo un rendimiento del -17.9% el año pasado.

Rentabilidad vs. Mercado: SAN1 N obtuvo unos resultados inferiores a los del mercado MX, que fue del 1.4% el año pasado.

Volatilidad de los precios

Is SAN1 N's price volatile compared to industry and market?
SAN1 N volatility
SAN1 N Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	5.5%
Market Average Movement	3.8%
10% most volatile stocks in MX Market	6.2%
10% least volatile stocks in MX Market	1.9%

Precio estable de las acciones: SAN1 N no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de SAN1 N en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1994	91,573	Paul Hudson	www.sanofi.com

Resumen de fundamentos de Sanofi

¿Cómo se comparan los beneficios e ingresos de Sanofi con su capitalización de mercado?
Estadísticas fundamentales de SAN1 N
Capitalización bursátil	Mex$2.15t
Beneficios(TTM)	Mex$168.79b
Ingresos (TTM)	Mex$850.82b

12.7x

Ratio precio-beneficio (PE)

2.5x

Ratio precio-ventas (PS)

¿Está SAN1 N sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de SAN1 N
Ingresos	€45.70b
Coste de los ingresos	€13.92b
Beneficio bruto	€31.78b
Otros gastos	€22.71b
Beneficios	€9.07b

Últimos beneficios comunicados

Sep 30, 2023

Próxima fecha de beneficios

Feb 01, 2024

Beneficios por acción (BPA)	7.23
Margen bruto	69.54%
Margen de beneficio neto	19.84%
Ratio deuda/patrimonio	28.8%

¿Cómo se ha desempeñado SAN1 N a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

3.9%

Rentabilidad actual por dividendo

52%

Ratio de pagos

Resumen de acción SAN1 N

Recompensas

Análisis de riesgos

Competidores de Sanofi

BMV:LAB B

Mex$13.6b

NYSE:PFE

US$149.0b

NYSE:BMY

US$99.3b

LSE:GSK

UK£66.8b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Sanofi Announces Quebec's INESSS Recommends BEYFORTUS® for Prevention of RSV for All Infants 8 Months of Age and Younger

Sanofi Announces Launch of Verorab® (Sanofi Inactivated Rabies Vaccine) in the UK for Pre-exposure and Post-exposure Prophylaxis of Rabies in All Age Groups

Sanofi Announces Phase 2b Results for Amlitelimab Support Potential for Best-In-Class Maintenance of Response in Atopic Dermatitis

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts Dupixent®? (Dupilumab) Sbla for Treatment of Copd with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. and Sanofi Announces the Ministry of Health, Labor and Welfare in Japan Grants Marketing and Manufacturing Authorization for Dupixent (Dupilumab) for the Treatment of Chronic Spontaneous Urticaria

Sanofi Reports Impairment of Intangible Assets for the Fourth Quarter Ended December 31, 2023

Recent updates

Sanofi Announces Quebec's INESSS Recommends BEYFORTUS® for Prevention of RSV for All Infants 8 Months of Age and Younger

Sanofi Announces Launch of Verorab® (Sanofi Inactivated Rabies Vaccine) in the UK for Pre-exposure and Post-exposure Prophylaxis of Rabies in All Age Groups

Sanofi Announces Phase 2b Results for Amlitelimab Support Potential for Best-In-Class Maintenance of Response in Atopic Dermatitis

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts Dupixent®? (Dupilumab) Sbla for Treatment of Copd with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. and Sanofi Announces the Ministry of Health, Labor and Welfare in Japan Grants Marketing and Manufacturing Authorization for Dupixent (Dupilumab) for the Treatment of Chronic Spontaneous Urticaria

Sanofi Reports Impairment of Intangible Assets for the Fourth Quarter Ended December 31, 2023

Sanofi Provides Earnings Guidance for the Fiscal Year 2024

Regeneron Pharmaceuticals, Inc. and Sanofi Announce That U.S. Food and Drug Administration Approves Dupixent®? (Dupilumab) for the Treatment of Children Aged 1 Year and Older with Eosinophilic Esophagitis

Sanofi to Report Q3, 2024 Results on Oct 25, 2024

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Updates the Label for Dupixent (Dpilumab)

Sanofi Appoints Brian Foard as Head of Specialty Care Global Business Unit and Member of Executive Committee

Sanofi to Report Q4, 2023 Results on Feb 01, 2024

Sanofi Announces Dupixent Significantly Reduced (34%) Exacerbations, Confirming Positive Published Results from the Landmark Phase 3 Boreas Trial

Sanofi to Report Q2, 2024 Results on Jul 25, 2024

Investor sentiment deteriorates as stock falls 17%

Third quarter 2023 earnings released: EPS: €2.02 (vs €1.66 in 3Q 2022)

Sanofi Reiterates Earnings Guidance for the Year 2023

Sanofi Announces Positive Results from a Phase 3 Trial Demonstrated the Efficacy and Safety Profile of Dupixent (Dupilumab) for Up to One Year (52 Weeks) in Children Aged 1 to 11 Years

Regeneron Pharmaceuticals, Inc. and Sanofi Provide Update on Dupixent®? (Dupilumab) sBLA for Chronic Spontaneous Urticaria

Sanofi Delivers First Medicines from Global Health Unit's Impact Brand Portfolio

Sanofi Reportedly Explores Potential Acquisition of Mirati Therapeutics

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepted for Priority Review

Sanofi S.A. and Sobi Announce Once-Weekly ALTUVIIIO Approved in Japan as A New Class of Factor VIII Therapy for Hemophilia A

Atnahs Pharma UK Limited acquired Global Central Nervous System Portfolio from Sanofi (ENXTPA:SAN).

Sanofi Announces Changes to Its Executive Committee

Sanofi, Annual General Meeting, Apr 30, 2024

Sanofi Announce that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices

Sanofi Provides Earnings Guidance for the Year 2023

SK Bioscience and Sanofi Announce Positive Results from Phase II Study of 21-Valent Pneumococcal Conjugate Vaccine Candidate

Sanofi Approves Distribution of A Cash Dividend, Payable on June 1, 2023

Sanofi Announces New Data from the Harmonie Phase 3B Clinical Trial Show an 83.21% Reduction in RSV Infant Hospitalizations in a Real-World Clinical Trial Setting

Upcoming dividend of €3.56 per share at 3.5% yield

Upcoming dividend of €3.56 per share at 3.5% yield

Sanofi Applauds Supreme Court Ruling Supporting Scientific Innovation by Striking Down Amgen's Asserted Pcsk9 Patent Claims in Amgen V Sanofi

Full year 2022 earnings released: EPS: €6.69 (vs €4.97 in FY 2021)

Sanofi Announces Executive Changes

Full year 2022 earnings released: EPS: €5.37 (vs €4.97 in FY 2021)

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Sanofi

12.7x

2.5x

Beneficios e Ingresos

Dividendos

3.9%

52%